ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
A Serum-Stable Antimicrobial Peptide-Based Delivery Platform for Selective Treatment of Nontargetable and Chemoresistant Tumors.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Serum-Stable Antimicrobial Peptide-Based Delivery Platform for Selective Treatment of Nontargetable and Chemoresistant Tumors.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibody-drug conjugates (ADCs) have transformed cancer therapy but remain limited by their dependence on internalizing antigens, poor applicability to untargetable tumors, and susceptibility to drug resistance. Therefore, a modular antimicrobial-peptide (AMP)-based therapeutic system centered on a rationally designed conjugate, 270, is presented, which integrates three optimized components: a selectivity-enhanced AMP core via a membrane affinity reconstruction strategy, a conformation-driven polyethylene glycolylated blocker to minimize off-target effects, and an N-terminal cap to improve stability in human serum. By targeting nonendocytic membrane surface receptors via small-molecule ligands, conjugate 270 exhibits potent and selective cytotoxicity against target tumor cells, effectively eliminating the majority of tumor cells within a few hours. Meanwhile, it exhibits high serum stability, minimal hemolysis, and negligible cytotoxicity toward normal cells at therapeutic concentrations. Mechanistic studies confirm ligand-dependent membrane localization, rapid depolarization, and disruption, along with mitochondrial dysfunction. Moreover, it demonstrates significant therapeutic efficacy against four cell lines resistant to conventional chemotherapeutic agents. While additional in vivo validation is warranted, this work lays the foundation for a flexible AMP-based approach to address untargetable and drug-resistant cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.